ID   KCL-22
AC   CVCL_2091
SY   KCL22; Kcl22; KCL22S
DR   BTO; BTO:0004137
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03472399
DR   BioSample; SAMN03473517
DR   BioSample; SAMN10988558
DR   CCLE; KCL22_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM01004
DR   Cosmic; 919142
DR   Cosmic; 924053
DR   Cosmic; 1019832
DR   Cosmic; 1026566
DR   Cosmic; 1070700
DR   Cosmic; 1078720
DR   Cosmic; 1176585
DR   Cosmic; 1436596
DR   Cosmic; 1498417
DR   Cosmic; 2009517
DR   Cosmic-CLP; 1330931
DR   DepMap; ACH-000983
DR   DSMZ; ACC-519
DR   GDSC; 1330931
DR   GEO; GSM887202
DR   GEO; GSM888275
DR   GEO; GSM1669981
DR   IARC_TP53; 2223
DR   JCRB; JCRB1317
DR   JCRB; NIHS0534
DR   LiGeA; CCLE_363
DR   LINCS_LDP; LCL-1105
DR   NCBI_Iran; C574
DR   PharmacoDB; KCL22_739_2019
DR   PRIDE; PXD000030
DR   Wikidata; Q54899647
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3332852;
RX   PubMed=6321612;
RX   PubMed=6576961;
RX   PubMed=9510473;
RX   PubMed=20417730;
RX   PubMed=22460905;
RX   PubMed=23754495;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: 24 hours (PubMed=6321612); ~24 hours (DSMZ).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=9510473; PubMed=31068700; Sanger).
CC   Sequence variation: BCR-ABL1 gene fusion.
CC   Sequence variation: Heterozygous for MSH6 p.Phe1088Serfs*2 (c.3261delC) and p.Phe1088Leufs*5 (c.3261dupC) (3261_3262insC) (PubMed=9510473).
CC   Sequence variation: TP53 p.Pro301fs (c.901delC) (CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.5%; East Asian, North=75.25%; East Asian, South=24.24%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0534; true.
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): Cosmic-CLP; DSMZ; JCRB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,11 (Cosmic-CLP; DSMZ)
ST   D13S317: 8,12 (JCRB)
ST   D16S539: 12
ST   D5S818: 10,12 (Cosmic-CLP; DSMZ)
ST   D5S818: 10,11 (JCRB)
ST   D7S820: 12 (Cosmic-CLP; DSMZ)
ST   D7S820: 11,12 (JCRB)
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   32Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 23
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=6321612; DOI=10.1002/stem.5530010205;
RA   Kubonishi I., Miyoshi I.;
RT   "Establishment of a Ph1 chromosome-positive cell line from chronic
RT   myelogenous leukemia in blast crisis.";
RL   Int. J. Cell Cloning 1:105-117(1983).
//
RX   PubMed=6576961; DOI=10.20772/cancersci1959.74.3_319;
RA   Kubonishi I., Machida K.-I., Sonobe H., Ohtsuki Y., Akagi T.,
RA   Miyoshi I.;
RT   "Two new human myeloid cell lines derived from acute promyelocytic
RT   leukemia and chronic myelocytic leukemia.";
RL   Gann 74:319-322(1983).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=20417730; DOI=10.1016/j.bbapap.2010.04.009;
RA   Colavita I., Esposito N., Martinelli R., Catanzano F., Melo J.V.,
RA   Pane F., Ruoppolo M., Salvatore F.;
RT   "Gaining insights into the Bcr-Abl activity-independent mechanisms of
RT   resistance to imatinib mesylate in KCL22 cells: a comparative
RT   proteomic approach.";
RL   Biochim. Biophys. Acta 1804:1974-1987(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23754495; DOI=10.1002/pmic.201200444;
RA   Colavita I., Esposito N., Quintarelli C., Nigro E., Pane F.,
RA   Ruoppolo M., Salvatore F.;
RT   "Identification of annexin A1 interacting proteins in chronic myeloid
RT   leukemia KCL22 cells.";
RL   Proteomics 13:2414-2418(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//